<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVEIpragliflozin, a <z:chebi fb="199" ids="26708">sodium</z:chebi>-<z:chebi fb="105" ids="17234">glucose</z:chebi> cotransporter 2 inhibitor, stimulates <z:hpo ids='HP_0003076'>glycosuria</z:hpo> and lowers glycemia in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) </plain></SENT>
<SENT sid="1" pm="."><plain>Objective of this study was to assess the pharmacodynamics of ipragliflozin in T2DM patients with <z:hpo ids='HP_0000082'>impaired renal function</z:hpo>.RESEARCH DESIGN AND METHODSGlycosuria was measured before and after a single ipragliflozin dose in 8 nondiabetic subjects and 57 T2DM patients (age 62 ± 9 years, fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> 133 ± 39 mg/dL, mean ± SD) with <z:mpath ids='MPATH_458'>normal</z:mpath> renal function (assessed as the estimated glomerular filtration rate) (eGFR(1) ≥90 mL · min(-1) · 1.73 m(-2)), mild (eGFR(2) ≥60 to &lt;90), moderate (eGFR(3) ≥30 to &lt;60), or severe reduction in eGFR (eGFR(4) ≤15 to &lt;30).RESULTSIpragliflozin significantly increased urinary <z:chebi fb="105" ids="17234">glucose</z:chebi> excretion in each eGFR class (P &lt; 0.0001) </plain></SENT>
<SENT sid="2" pm="."><plain>However, ipragliflozin-induced <z:hpo ids='HP_0003076'>glycosuria</z:hpo> declined (median [IQR]) across eGFR class (from 46 [33] mg/min in eGFR(1) to 8 [7] mg/min in eGFR(4), P &lt; 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain>Ipragliflozin-induced fractional <z:chebi fb="105" ids="17234">glucose</z:chebi> excretion (excretion/filtration) was 39 [27]% in the T2DM patients (pooled data), similar to that of the nondiabetic subjects (37 [17]%, P = ns) </plain></SENT>
<SENT sid="4" pm="."><plain>In bivariate analysis of the pooled data, ipragliflozin-induced <z:hpo ids='HP_0003076'>glycosuria</z:hpo> was directly related to eGFR and fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> (P &lt; 0.0001 for both, r(2) = 0.55), predicting a decrement in 24-h <z:hpo ids='HP_0003076'>glycosuria</z:hpo> of 15 g for each 20 mL/min decline in eGFR and an increase of 7 g for each 10 mg/dL increase in <z:chebi fb="105" ids="17234">glucose</z:chebi> above fasting normoglycemia.CONCLUSIONSIn T2DM patients, ipragliflozin increases <z:hpo ids='HP_0003076'>glycosuria</z:hpo> in direct, linear proportion to GFR and degree of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, such that its amount can be reliably predicted in the individual patient </plain></SENT>
<SENT sid="5" pm="."><plain>Although absolute <z:hpo ids='HP_0003076'>glycosuria</z:hpo> decreases with declining GFR, the efficiency of ipragliflozin action (fractional <z:chebi fb="105" ids="17234">glucose</z:chebi> excretion) is maintained in patients with severe <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> </plain></SENT>
</text></document>